we hereby informed you that the Board of Directors at their meeting held today i.e., 14th August 2025, Board Meeting commenced at 05:00 PM. concluded at 6:30 PM at the registered office of the company
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Limited's Board of Directors, at its meeting on August 14, 2025, approved the unaudited financial results for the quarter ended June 30, 2025. The company posted its first revenue from operations at Rs. 715 lacs, compared to no revenue in Q1 FY25. However, the company still reported a net loss of Rs. 49.98 lacs, with an EPS of (Rs. 0.21), only marginally better than the Rs. 54.57 lacs loss in the year-ago quarter. Total expenses stood at Rs. 766.60 lacs, driven primarily by stock-in-trade purchases of Rs. 675 lacs and employee costs of Rs. 37.81 lacs. The statutory auditor (M/s P P N And Company) issued an unqualified limited review report with no qualifications or emphasis of matter. Separately, the Board noted that Regulation 32 of SEBI LODR is not applicable as the company has not raised funds through any public, rights, or preferential issue.
First reported revenue is a positive operational signal, but persistent quarterly losses and expenses outpacing income indicate the company is yet to reach profitability. Investors should monitor whether revenue scales up sufficiently to cover costs in coming quarters.